Japan’s health ministry formally approved Novavax’s COVID-10 vaccine, Nuvaxovid, to combat the infections, according to a news release by Novavax on Tuesday.

  • The ministry’s approval comes after its expert panel endorsed the use of Novavax’s protein vaccine, which is developed with similar technology used in fighting infections.
  • Nuvaxovid is the first protein-based COVID-19 vaccine approved for use in adults aged 18 years and older in Japan.
  • The approval is based on Takeda’s New Drug Application submission, which included positive interim findings from a Phase 1/2 study performed in Japan and several studies conducted by Novavax.
  • The pharmaceutical company licensed and transferred its manufacturing technologies and is supplying the Matrix-M adjuvant to allow Takeda to manufacture the vaccine at its Hikari facility.

Takeda, the Marketing Authorization Holder for Nuvaxovid in Japan, will start the distribution of doses purchased by the Government of Japan as soon as possible. NVAX down -0.80%, PFE down -1.54%